Tonix Pharmaceuticals receives grant to advance development of TNX-1300 as a treatment for cocaine intoxication

Tonix Pharmaceuticals has received a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300 a recombinant enzyme that efficiently degrades and metabolizes cocaine. In 2021, more than 24,900 individuals in the U.S. died from drug overdose deaths involving cocaine^.